Cocktail-substrate approach-based high-throughput assay for evaluation of direct and time-dependent inhibition of multiple cytochrome P450 isoforms

Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 2, 2014, Pages 198-207

  Kozakai, Kazumasa ^a   Yamada, Yasuhiro ^a   Oshikata, Motoji ^b   Kawase, Taiji ^b   Suzuki, Etsuko ^b   Haramaki, Yukari ^b   Taniguchi, Hideki ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b Environmental Solution Center   (Japan)

Author keywords

Cocktail approach; CYP inhibition; Direct inhibition; Drug drug interaction; Time dependent inhibition; UPLC MS MS

Indexed keywords

AMFEBUTAMONE; AMODIAQUINE; BUFURALOL; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DICLOFENAC; ERYTHROMYCIN; FLUCONAZOLE; FLUVOXAMINE; FURAFYLLINE; ITRACONAZOLE; MEPHENYTOIN; MIDAZOLAM; PAROXETINE; PHENACETIN; TESTOSTERONE; TICLOPIDINE; TIENILIC ACID; CYTOCHROME P450 INHIBITOR; ISOENZYME;

ARTICLE; COCKTAIL SUBSTRATE APPROACH BASED HIGH THROUGHPUT ASSAY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; IC 50; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; COMPARATIVE STUDY; DRUG DEVELOPMENT; DRUG INTERACTION; ENZYME SPECIFICITY; ENZYMOLOGY; HIGH THROUGHPUT SCREENING; HUMAN; KINETICS; LIVER; LIVER MICROSOME; METABOLISM; PROCEDURES; REPRODUCIBILITY; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DISCOVERY; DRUG INTERACTIONS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ISOENZYMES; KINETICS; LIVER; MICROSOMES, LIVER; REPRODUCIBILITY OF RESULTS; SUBSTRATE SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84901232718     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-13-RG-093     Document Type: Article

References (31)

1. Soars, M. G., McGinnity, D. F., Grime, K. and Riley, R. J.: The pivotal role of hepatocytes in drug discovery. Chem. Biol. Interact., 168: 2-15 (2007).
2. Bachmann, K. A. and Lewis, J. D.: Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann. Pharmacother., 39: 1064-1072 (2005).
3. Wienkers, L. C. and Heath, T. G.: Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov., 4: 825-833 (2005).
4. Zhou, S. F.: Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab., 9: 310-322 (2008).
5. Friedman, M. A., Woodcock, J., Lumpkin, M. M., Shuren, J. E., Hass, A. E. and Thompson, L. J.: The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA, 281: 1728-1734 (1999).
6. Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M. and Bor, D. H.: Timing of new black box warnings and withdrawals for prescription medications. JAMA, 287: 2215-2220 (2000).
7. Kozakai, K., Yamada, Y., Oshikata, M., Kawase, T., Suzuki, E., Haramaki, Y. and Taniguchi, H.: Reliable high-throughput method for inhibition assay of 8 cytochrome P450 isoforms using cocktail of probe substrates and stable isotope-labeled internal standards. Drug Metab. Pharmacokinet., 27: 520-529 (2012).
8. Palmer, J. L., Scott, R. J., Gibson, A., Dickins, M. and Pleasance, S.: An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). Br. J. Clin. Pharmacol., 52: 555-561 (2001).
9. Ono, S., Hatanaka, T., Hotta, H., Tsutsui, M., Satoh, T. and Gonzalez, F. J.: Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics, 5: 143-150 (1995).
10. White, R. E.: High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu. Rev. Pharmacol. Toxicol., 40: 133-157 (2000).
11. Riley, R. J., Grime, K. and Weaver, R.: Time-dependent CYP inhibition. Expert Opin. Drug Metab. Toxicol., 3: 51-66 (2007).
12. US FDA: Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling Recommendations. Rockville, Food and Drug Administration, 2012, pp. 1-75.
13. EMA: Guideline on the investigation of drug interactions. London, UK, European Medicines Agency, 2012, pp. 1-60.
14. US FDA: Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. Rockville, Food and Drug Administration, 2006, pp. 1-55.
15. Walsky, R. L., Astuccio, A. V. and Obach, R. S.: Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J. Clin. Pharmacol., 46: 1426-1438 (2006).
16. Peng, C. C., Templeton, I., Thummel, K. E., Davis, C., Kunze, K. L. and Isoherranen, N.: Evaluation of 6β-hydroxycortisol, 6β- hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo. Clin. Pharmacol. Ther., 89: 888-895 (2011).
17. Lukkari, E., Taavitsainen, P., Juhakoski, A. and Pelkonen, O.: Cytochrome P450 specificity of metabolism and interactions of oxybutynin in human liver microsomes. Pharmacol. Toxicol., 82: 161-166 (1998).
18. Hesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I. and Greenblatt, D. J.: CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos., 28: 1176-1183 (2000).
19. von Moltke, L. L., Greenblatt, D. J., Duan, S. X., Schmider, J., Wright, C. E., Harmatz, J. S. and Shader, R. I.: Human cytochromes mediating N-demethylation of fluoxetine in vitro. Psychopharmacology (Berl.), 132: 402-407 (1997).
20. Sudsakorn, S., Skell, J., Williams, D. A., O'Shea, T. J. and Liu, H.: Evaluation of 3-O-methylfluorescein as a selective fluorometric substrate for CYP2C19 in human liver microsomes. Drug Metab. Dispos., 35: 841-847 (2007).
21. Taavitsainen, P., Anttila, M., Nyman, L., Karnani, H., Salonen, J. S. and Pelkonen, O.: Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes. Pharmacol. Toxicol., 86: 215-221 (2000).
22. Draper, A. J., Madan, A. and Parkinson, A.: Inhibition of coumarin 7-hydroxylase activity in human liver microsome. Arch. Biochem. Biophys., 341: 47-61 (1997).
23. Niwa, T., Shiraga, T. and Takagi, A.: Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol. Pharm. Bull., 28: 1805-1808 (2005).
24. Grimm, S. W., Einolf, H. J., Hall, S. D., He, K., Lim, H. K., Ling, K. H., Lu, C., Nomeir, A. A., Seibert, E., Skordos, K. W., Tonn, G. R., Van Horn, R., Wang, R. W., Wong, Y. N., Yang, T. J. and Obach, R. S.: The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab. Dispos., 37: 1355-1370 (2009).
25. Obach, R. S., Walsky, R. L. and Venkatakrishnan, K.: Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos., 35: 246-255 (2007).
26. Berry, L. M. and Zhao, Z.: An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6, and CYP2C9 in human liver microsomes. Drug Metab. Lett., 2: 51-59 (2008).
27. Mori, K., Hashimoto, H., Takatsu, H., Tsuda-Tsukimoto, M. and Kume, T.: Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development. Xenobiotica, 39: 415-422 (2009).
28. Grime, K. H., Bird, J., Ferguson, D. and Riley, R. J.: Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur. J. Pharm. Sci., 36: 175-191 (2009).
29. Burt, H. J., Galetin, A. and Houston, J. B.: IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4. Xenobiotica, 40: 331-343 (2010).
30. Parkinson, A., Kazmi, F., Buckley, D. B., Yerino, P., Paris, B. L., Holsapple, J., Toren, P., Otradovec, S. M. and Ogilvie, B. W.: An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes. Drug Metab. Dispos., 39: 1370-1387 (2011).
31. Watanabe, A., Nakamura, K., Okudaira, N., Okazaki, O. and Sudo, K.: Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metab. Dispos., 35: 1232-1238 (2007).